Get the Stockscreener App
233.74
0.76%
-1.80
After Hours:
232.82
-0.92
-0.39%
Natera Inc stock is traded at $233.74, with a volume of 397.70K.
It is down -0.76% in the last 24 hours and down -1.43% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$235.54
Open:
$233.45
24h Volume:
397.70K
Relative Volume:
0.30
Market Cap:
$32.59B
Revenue:
$2.12B
Net Income/Loss:
$-309.19M
P/E Ratio:
-102.33
EPS:
-2.2841
Net Cash Flow:
$93.57M
1W Performance:
+0.77%
1M Performance:
-1.43%
6M Performance:
+38.99%
1Y Performance:
+46.42%
1-Day Range:
$233.36
$236.33
1-Week Range:
$231.07
$237.04
52-Week Range:
$125.38
$246.90
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
233.74 | 32.85B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
580.74 | 217.58B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
230.32 | 163.50B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
688.48 | 54.95B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
138.39 | 39.21B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
226.92 | 38.49B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Is Natera’s 486% Three Year Surge Still Justified by Its Fundamentals? - Yahoo Finance
3 Reasons We’re Fans of Natera (NTRA) - Barchart.com
3 Reasons We're Fans of Natera (NTRA) - Finviz
J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum - Finviz
Natera co-founder Sheena Jonathan sells $338913 in stock - Investing.com India
Canaccord Genuity Maintains Natera (NTRA) Buy Recommendation - Nasdaq
Natera (NTRA): Revisiting Valuation After New JAMA Oncology Data on Signatera’s Colorectal Cancer Benefit - simplywall.st
Natera (NASDAQ:NTRA) Price Target Raised to $285.00 - MarketBeat
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Will Natera Inc. stock outperform tech sector in 2025July 2025 Analyst Calls & Real-Time Volume Analysis Alerts - ulpravda.ru
How Natera Inc. stock performs in stagflationMarket Weekly Review & Precise Entry and Exit Recommendations - ulpravda.ru
Zevenbergen Capital Investments LLC Sells 11,417 Shares of Natera, Inc. $NTRA - MarketBeat
Natera (NTRA): Assessing Valuation After a Multi‑Year Share Price Surge - Yahoo Finance
Natera, Inc. $NTRA Shares Bought by Orion Porfolio Solutions LLC - MarketBeat
Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative? - simplywall.st
How Investors Are Reacting To Natera (NTRA) Trial Data Showing Signatera’s 40% Risk Reduction In CRC - Yahoo Finance
Dir Sheena Files To Sell 4,500 Of Natera Inc [NTRA] - TradingView — Track All Markets
Can Natera Inc. stock beat analyst upgradesJuly 2025 Snapshot & Weekly High Return Opportunities - DonanımHaber
Is Natera’s 425.8% Three Year Surge Still Supported by Its Growth Story in 2025? - simplywall.st
Is Natera Inc. stock a safe buy before earningsQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Profit Recap: Will Natera Inc. stock outperform tech sector in 20252025 Biggest Moves & Growth Focused Entry Point Reports - Улправда
NTRA: Natera's Phase III Study Highlights Celecoxib's Efficacy i - GuruFocus
Study shows celecoxib improves survival in certain colorectal cancer patients - Investing.com India
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer - New Castle News
Is Natera Inc. stock attractive after correctionJuly 2025 Opening Moves & Weekly Chart Analysis and Guides - Улправда
Thrivent Financial for Lutherans Cuts Stake in Natera, Inc. $NTRA - MarketBeat
Assenagon Asset Management S.A. Purchases 80,684 Shares of Natera, Inc. $NTRA - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Natera (NTRA) - The Globe and Mail
Natera (NTRA) director and co-founder discloses stock gift and sales - Stock Titan
Dir Sheena Sells 3,070 ($696.9K) Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera’s Signatera Test Gains Validation in Key Breast Cancer Study - AD HOC NEWS
Dir Sheena Files To Sell 9,210 Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera, Inc.'s (NASDAQ:NTRA) Business Is Trailing The Industry But Its Shares Aren't - 富途牛牛
Solomon Moshkevich Sells 4,692 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Insider Selling: Natera (NASDAQ:NTRA) Director Sells 48,419 Shares of Stock - MarketBeat
Officer Moshkevich Acquires 17,684 Of Natera Inc [NTRA] - TradingView — Track All Markets
Dir Rosenman Sells 48,419 ($11M) Of Natera Inc [NTRA] - TradingView — Track All Markets
NATERA INC : JEFFERIES RAISES TARGET PRICE TO $275 FROM $230 - 富途牛牛
Natera’s cancer test improves risk assessment in breast cancer patients By Investing.com - Investing.com Nigeria
Natera’s cancer test improves risk assessment in breast cancer patients - Investing.com
Natera, Inc. $NTRA Shares Bought by New England Research & Management Inc. - MarketBeat
Natera (NASDAQ: NTRA) I-SPY 2 study ties Signatera ctDNA status to 3-year DRFS, recurrence risk - Stock Titan
NeoGenomics (NEO): Assessing Valuation After Legal Win Over Natera and New Oncology Data Releases - simplywall.st
Jefferies raises Natera stock price target to $275 on oncology growth - Investing.com Nigeria
Barclays Raises Natera (NTRA) Price Target to $270 | NTRA Stock News - GuruFocus
NTRA: JP Morgan Raises Price Target to $260 with Overweight Rati - GuruFocus
Natera (NASDAQ:NTRA) Given New $260.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Natera dismisses appeal in patent case against NeoGenomics By Investing.com - Investing.com Nigeria
Natera dismisses appeal in patent case against NeoGenomics - Investing.com India
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litig - pharmiweb.com
NeoGenomics Says Natera Withdraws Appeal in Patent Case - marketscreener.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):